… Additionally, assessment of clinical outcomes with initial EGFR-TKI therapy revealed that,
albeit not statistically significant, both ORR and PFS were better in T790M-positive than T790M-…

… Results Our patient cohort included 69 T790M + patients and 28 T790M − patients. Patients
… Our results indicate that T790M + patients have a significantly longer PFS on first-line TKI …

… However, it was reported that this mutation may exist before drug exposure. The objective of
… the clinical outcomes are affected by the percentage of preexisting T790M mutations within …

… factor receptor (EGFR) mutation. However, the clinical outcomes among the three EGFR …
We aimed to evaluate clinical outcomes and secondary EGFR T790M mutation among the …

… EGFR T790M mutation occurs in half of non-small cell lung cancer (NSCLC) patients with …
an invasive clinical procedure. Here, we dynamically monitored T790M mutation in circulating …

… However, in another study correlation between the clinical outcome and the ctDNA T790M
mutation status (detected by SABER) revealed that PFS of positive group was significantly …

… However, the origin of T790M and its impact on clinical outcomes is … the results of this study
reliably show that the de novo T790M mutation plays an important role in the clinical outcome …

… It should be noticed that T790M specific PNA only enriched T790M mutation … mutation
detection in cfDNA. In terms of clinical outcome analysis, our results indicated that T790M-positive …

… However, few papers have focused on the impact of different first-line EGFR-TKIs to the
clinical outcomes of sequential osimertinib treatment in patients with secondary T790M mutation. …

… sensitizing EGFR mutations before exposure to any kind of EGFR-TKIs. The clinical outcomes
of … In our study, most of the patients with de novo T790M mutation received Osimertinib …